Sulfhydryl donor used to reduce the urotoxic effects of antineoplastic alkylating agents; also has mucolytic activity. Prepn: I. M. Lipovich, J. Appl. Chem. USSR 18, 718 (1945); C. H. Schramm et al., J. Am. Chem. Soc. 77, 6231 (1955). Synthesis and properties: V. E. Petrun'kin, C.A. 51, 5693a (1957); ibid. 54, 24379c (1960). Use as mucolytic: NL 6605816; H. Morren, US 3567835 (1966, 1971 both to U.C.B.); as uroprotective agent: N. Brock, DE 2756018; idem, US 4220660 (1979, 1980 both to Asta-Werke AG). Pharmacology, toxicity, and uroprotective effects in animals: N. Brock et al., Eur. J. Cancer Clin. Oncol. 18, 1377 (1982). HPLC determn in plasma and urine: C. A. James, H. J. Rogers, J. Chromatogr. 382, 394 (1986). Clinical pharmacokinetics: C. A. James et al., Br. J. Clin. Pharmacol. 23, 561 (1987). Clinical study of mucolytic effects: M. Tekeres et al., Clin. Ther. 4, 56 (1981). Symposium on pharmacology, toxicity and clinical uroprotective efficacy: Cancer Treat. Rev. 10, Suppl. A, 1-192 (1983). Reviews: I. C. Shaw, M. I. Graham, ibid. 14 67-86 (1987); S. E. Schoenike, W. J. Dana, Clin. Pharm. 9, 179-191 (1990).
Mucolytic; antineoplastic adjunct (uroprotective).
Antineoplastic Adjunct; Uroprotective; Mucolytic